Skip to content

    Alembic Pharmaceuticals Limited

    APLLTDGood
    Healthcare·6 May 2025
    Management Summary

    Alembic Pharma delivered a strong finish to FY25, characterized by robust double-digit growth in international markets and a recovery in the US generics segment. While gross margins have moderated to 70% due to product mix, management is focused on operating leverage from new facilities to drive EBITDA margins toward 18-20%. The company is pivoting its R&D toward complex injectables and peptides, aiming for high-value launches in FY26 and beyond.

    Highlights

    8

    • Q4 Revenue grew 17% YoY to ₹1,770 crores, driven by strong international performance.

    • FY25 full-year revenue reached ₹6,672 crore, a 7% increase over the previous year.

    • EBITDA margin remained stable at 16% for both Q4 and the full year FY25.

    • US Generics business grew 20% in Q4 to ₹508 crores; Ex-US (ROW) Generics surged 43% to ₹375 crores.

    • India business grew 8% in Q4 to ₹545 crores, with Animal Health growing 19%.

    • R&D spend for FY25 was ₹522 crores (approx. 8% of sales), with guidance increasing to ₹600-650 crores for FY26.

    • Net Profit for Q4 stood at ₹157 crores, impacted by higher tax provisions.

    • Management announced a dividend of ₹11 per equity share (550% on par value of ₹2).

    What Changed1

    vs Q1 FY26

    Guidance items6 → 7 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,770 Cr+17%YoY
    2. 02EBITDA₹286 Cr+9%YoY
    3. 03EBITDA Margin16%
    4. 04Net Profit₹157 Cr
    5. 05EPS₹7.98-12%YoY

    Segment breakdown

    • India Business₹545 Cr30.8%
    • US Generics₹508 Cr28.7%
    • Ex-US Generics (ROW)₹375 Cr21.2%
    • API Business₹342 Cr19.3%
    Donut· Share of Revenue

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    US Business Growth
    15%
    		Medium
    Revenue
    ROW Business Growth
    12-15%
    		Medium
    Revenue
    India Business Growth
    10% plus
    		High
    Revenue
    API Business Growth
    10%
    		Medium
    Margin
    EBITDA Margin Target
    18-20%
    		Medium
    Capex
    Maintenance and Regular Capex
    ₹400-450 crores
    		High
    Other
    R&D Expense
    ₹600-650 crores
    		High

    Risks & concerns

    4
    RiskSeverity

    US Pricing Pressure

    Pricing pressure remains persistent in the U.S. market on a product-to-product basis. — Management acknowledged

    medium

    Chinese Competition in API

    Chinese players are back in the market with aggressive pricing, impacting API business margins and volumes. — Management acknowledged

    medium

    Inventory Buildup

    Inventory levels rose due to anticipated US launches and facility utilization; management expects this to taper down in FY26. — Analyst acknowledged

    low

    Areas of Evasion(1)

    • Specific high-value product names for the 15+ US launches were kept general (20-30% interesting opportunities).

    Q&A highlights

    3

    “No one has enough capacity in the U.S... only about 10% of the volumes can be manufactured in the U.S. So the rest of it is, going to be a huge shortfall.”

    Management clarifies that US tariffs would be a macro industry issue rather than a company-specific risk, as domestic US capacity is insufficient to meet demand.

    asked by Damayanti Kerai

    2 min read5 chapters

    Detailed Narrative

    01

    International Markets Drive Growth

    The International business was the primary growth engine in Q4, with US Generics growing 20% to ₹508 crores and Ex-US (ROW) Generics surging 43% to ₹375 crores. For FY26, management expects the US business to maintain mid-teen growth (approx. 15%) supported by a pipeline of 15+ new launches. The ROW business is also projected to grow steadily between 12-15%.

    02

    Strategic Pivot to Complex Injectables and Peptides

    Alembic is significantly increasing its R&D investment to ₹600-650 crores in FY26, with 30-35% of this spend dedicated to peptides and complex injectables. The company aims to be a 'Day 1' player for Tirzepatide in all markets, although it acknowledges being late for the US Semaglutide launch. Nearly 45% of new filings are now focused on the injectable segment.

    03

    Margin Expansion through Operating Leverage

    While gross margins have stabilized at 70% due to product mix and price erosion, management is targeting an EBITDA margin of 18-20% over the next few years. This expansion is expected to come from higher capacity utilization at three new facilities, particularly the newer injectable plants. Operating leverage from optimized R&D spend (down from 14% to 8-9% of sales) will also contribute to profitability.

    04

    India Business and Animal Health Resilience

    The India business grew 8% in Q4, reaching ₹545 crores, with a full-year topline of ₹2,339 crores. Animal Health remains a 'bright spot,' growing 19% in the quarter and 21% for the full year. Management is confident in driving 10% plus growth in the domestic market for FY26, supported by 14 new launches in the past year and a stable field force of 5,500 MRs.

    05

    API Business Recovery and Capex Outlook

    The API business returned to growth in Q4 (+4%) after a 9% decline for the full year, primarily due to pricing pressure from Chinese competitors. Management expects a 10% recovery in API for FY26. Capex is expected to moderate📎 to ₹400-450 crores as major projects like the Pithampur facility and peptide blocks are now commissioned.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.